KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Debt Repayments (2016 - 2018)

Vertex Pharmaceuticals (VRTX) has 7 years of Long-Term Debt Repayments data on record, last reported at $8.1 million in Q4 2018.

  • For Q4 2018, Long-Term Debt Repayments rose 76.56% year-over-year to $8.1 million; the TTM value through Dec 2018 reached $27.9 million, up 48.58%, while the annual FY2018 figure was $27.9 million, 48.58% up from the prior year.
  • Long-Term Debt Repayments reached $8.1 million in Q4 2018 per VRTX's latest filing, up from $5.7 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $264.1 million in Q3 2014 and bottomed at -$272.9 million in Q4 2014.
  • Average Long-Term Debt Repayments over 5 years is $5.3 million, with a median of $4.8 million recorded in 2017.
  • Peak YoY movement for Long-Term Debt Repayments: surged 167246.2% in 2014, then plummeted 99.96% in 2015.
  • A 5-year view of Long-Term Debt Repayments shows it stood at -$272.9 million in 2014, then soared by 107.21% to $19.7 million in 2015, then crashed by 78.31% to $4.3 million in 2016, then rose by 7.97% to $4.6 million in 2017, then soared by 76.56% to $8.1 million in 2018.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $8.1 million in Q4 2018, $5.7 million in Q3 2018, and $4.9 million in Q2 2018.